Switching PCI Patients to Prasugrel from Clopidogrel Reduces Max Platelet Aggregation
September 15, 2010 – A study evaluating the level of platelet aggregation achieved after switching from clopidogrel (Plavix) 75 mg once-daily maintenance dosing plus aspirin to prasugrel (Effient) 10 mg once-daily maintenance dosing (MD) in patients with acute coronary syndrome (ACS) was published today in the Journal of the American College of Cardiology. In this phase II study, ACS patients who were switched to prasugrel (either 10 mg MD or 60 mg loading dose (LD) followed by 10 mg MD plus aspirin demonstrated a statistically significant greater reduction in maximum platelet aggregation (MPA) after one week when compared with patients who remained on maintenance therapy with clopidogrel.
The Switching Anti-Platelet Study (SWAP) was sponsored by Daiichi Sankyo Co. Ltd. and Eli Lilly and Co.
Platelet aggregation is a critical step in the formation of blood clots, which pose a significant risk to patients following an ACS event, including heart attack and heart-related chest pain. The study provides further evidence to suggest that Effient reduces platelet aggregation to a greater extent among ACS patients compared to Plavix.
Of the 128 patients who completed the study, 100 patients were eligible to be included in the platelet function analysis. After a 10-14 day run-in phase with open label clopidogrel 75 mg once daily plus aspirin, patients were randomly assigned to one of the following three treatments: remain on clopidogrel 75 mg plus aspirin for seven days (n=33); switch to prasugrel 10 mg plus aspirin for seven days (n=36); or switch to prasugrel 60 mg loading dose plus aspirin followed by prasugrel 10 mg plus aspirin daily for six days (n=31).
At day seven, MPA (as measured using 20 micromolar ADP) was statistically significantly lower in patients switched to prasugrel 10 mg plus aspirin when compared with the patients who remained on clopidogrel (41.1 vs. 55 percent, p <0.0001) and in those patients switched to prasugrel 60 mg LD followed by prasugrel 10 mg MD vs. clopidogrel (41.0 percent vs. 55.0 percent, p < 0.0001).
"These findings are important because they provide new insights into potential differences in the levels of platelet inhibition that can be achieved with dual oral antiplatelet therapy in patients with ACS," said Dominick J. Angiolillo, M.D., assistant professor, Department of Medicine, Division of Cardiology, University of Florida College of Medicine, Jacksonville, and lead author of the paper. "The data showed that Effient plus aspirin may provide additional reduction in platelet aggregation in ACS patients over those taking standard-dose clopidogrel plus aspirin. However, a larger study would be needed to assess the potential impact of switching on cardiovascular outcomes."
The SWAP study was not designed to evaluate efficacy or safety endpoints.
For more information http://pi.lilly.com/us/effient.pdf or www.Effient.com
More like this
- New Data and Recent Advances in Antiplatelet Agents
- New Analysis Shows Prasugrel Cost-Effective Compared with Clopidogrel
- New Analysis of Data Presented at AHA: Prasugrel’s Effect on Cardiovascular Events in STEMI Patients According to Timing of PCI
- New Approaches, Drugs for Antiplatelet Therapy
- FDA Clears Effient, May be Serious Competitor to Plavix